Recovering scientist turned early stage VC A biotech optimist fighting gravity

Mariana Oncology’s Radiopharm Platform Acquired By Novartis
May 6, 2024

Novartis recently announced the acquisition of Mariana Oncology, an emerging biotech focused on advancing a radioligand therapeutics platform, for up to $1.75 billion in upfronts and future milestones. The capstone of its three short years of operations, this acquisition represents

Leave a comment

Stars and Scars… Some Lessons Learned About Leadership
May 2, 2024

By Arthur O. Tzianabos, PhD, CEO of Lifordi Immunotherapeutics, as part of the From the Trenches feature of LifeSciVC As the biotech industry continues to pick up steam, I have been getting a number of phone calls from folks in

Leave a comment

The Biotech Startup Contraction Continues… And That’s A Good Thing
April 26, 2024

Venture creation in biotech is witnessing a sustained contraction. After the pandemic bubble’s over-indulgence, the venture ecosystem appears to have reset its pace of launching new startups. According to the latest Pitchbook data, venture creation in biotech hit its slowest

Leave a comment

Pharmacology: The Anchor for Nearly Every Diligence
April 25, 2024

By Haojing Rong and Aimee Raleigh, as part of the From The Trenches feature of LifeSciVC This blog post is the second in a series on key diligence concepts and questions. If you missed the intro blog post yesterday, click

Leave a comment

Deconstructing the Diligence Process: An Approach to Vetting New Product Theses
April 24, 2024

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Ever wondered what goes into diligencing a new idea, program, company, or platform? While each diligence is unique and every investor will have

Leave a comment

Lessons From A Private Funding Round: Science, Relationships, And Experience
April 2, 2024

By Mike Cloonan, CEO of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC An insightful piece on this blog following the JPM healthcare conference noted the “refreshing burst of enthusiasm” in the biotech sector. It’s true

Leave a comment

IFM’s Hat Trick and Reflections On Option-To-Buy M&A
March 13, 2024

Today IFM Therapeutics announced the acquisition of IFM Due, one of its subsidiaries, by Novartis. Back in Sept 2019, IFM granted Novartis the right to acquire IFM Due as part of an “option to buy” collaboration around cGAS-STING antagonists for

Leave a comment

Every Second Counts
March 11, 2024

By Aoife Brennan, former CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC I have recently completed a turn around the biotech sun: a seven-year assignment at Synlogic that ended this year when an early readout

Leave a comment

March Madness – Biotech Style
March 8, 2024

By Robert Clarke, CEO of Kinaset, as part of the From The Trenches feature of LifeSciVC As I write, I am on the train back from New York after watching my son’s NYU basketball team play in the 2024 D3

Leave a comment

More than Just Words: Prioritizing Patient-Centered Drug Development
February 27, 2024

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Patients and their care partners are at the center of our work in the life sciences industry – but at what point during

Leave a comment

Greater Than The Sum Of The Parts: A Framework For Leading Enterprises In Non-Traditional Ways
February 16, 2024

By Ankit Mahadevia, former CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC The right leaders in the right structure can power companies to great things. The general consensus is that all companies need a

Leave a comment

The Long and Winding (Biotech) Road…
January 25, 2024

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From the Trenches feature of LifeSciVC Well, this is a first…. while I have read and enjoyed the the LifeSci VC blog for years, being asked to contribute for

Leave a comment



Verified by ExactMetrics